翰宇药业：12月5日翰宇药业龙华总部研发中心实验室“零缺陷”通过FDA检查

Core Insights - The company Hanyu Pharmaceutical has successfully passed the FDA's "zero defect" inspection for its laboratory at the Longhua headquarters on December 5, 2025, marking the second consecutive "zero defect" inspection in 2023 [1] - The company's raw material production base in Wuhan also achieved a "zero defect" status on November 29, 2024, supporting its global expansion efforts [1] - Hanyu Pharmaceutical's total production capacity for peptide raw materials exceeds 5 tons [1] Company Developments - Hanyu Pharmaceutical's laboratory has demonstrated compliance with FDA standards, enhancing its credibility and operational efficiency [1] - The successful inspections are expected to bolster the company's capacity to meet the global demand for pharmaceutical formulations, estimated at 20 million doses [1] - The company's strategic focus on expanding its production capabilities aligns with its goal of supporting international market growth [1]